Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

• Main Authors: Rong Tang (Author), Ying Zeng (Author), Yu Zhou (Author), Qi Liang (Author), Wei Kang (Author), Zhonghua Yang (Author), Xiaoxiang Zheng (Author), Xia Zang (Author), Hongxing Pan (Author), Jing Jin (Author), Fengcai Zhu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTBackground Vaccination remains the cornerstone of defense against COVID-19 globally. This study aims to assess the safety and immunogenicity profile of innovative vaccines LYB001.Research design and methods This was a randomized, double-blind, parallel-controlled trial, in 100 healthy Chines...